Angiogenesis therapy for brain infarction using a slow-releasing drug delivery system for fibroblast growth factor 2

Biochemical and Biophysical Research Communications

Volumn 432, Issue 1, 2013, Pages 182-187

  Ito, Yoshiro ^a   Tsurushima, Hideo ^a,b   Sato, Masayuki ^a   Ito, Atsuo ^b   Oyane, Ayako ^b   Sogo, Yu ^b   Matsumura, Akira ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Angiogenesis therapy; Brain infarction; Drug delivery system; Fibroblast growth factor 2

Indexed keywords

APATITE; FIBROBLAST GROWTH FACTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION; BRAIN REGION; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EXTERNAL CAPSULE; FLUORESCENCE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMPLANTATION; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; APATITES; BRAIN; BRAIN INFARCTION; CAPILLARIES; DELAYED-ACTION PREPARATIONS; FIBROBLAST GROWTH FACTOR 2; MALE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84875371120     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.013     Document Type: Article

References (26)

1. Ay H., Ay I., Koroshetz W.J., et al. Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc. Dis. 1999, 9:131-135.
2. Wada K., Sugimori H., Bhide P.G., et al. Effect of basic fibroblast growth factor treatment on brain progenitor cells after permanent focal ischemia in rats. Stroke 2003, 34:2722-2728.
3. Guo H., Huang L., Cheng M., et al. Serial measurement of serum basic fibroblast growth factor in patients with acute cerebral infarction. Neurosci. Lett. 2006, 393:56-59.
4. Kawamata T., Alexis N.E., Dietrich W.D., et al. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat. J. Cereb. Blood Flow Metab. 1996, 16:542-547.
5. Whalen G.F., Shing Y., Folkman J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors 1989, 1:157-164.
6. Hondermarck H., Courty J., Boilly B., et al. Distribution of intravenously administered acidic and basic fibroblast growth factors in the mouse. Experientia 1990, 46:973-974.
7. Sogo Y., Ito A., Fukasawa K., et al. Coprecipitation of cytochrome C with calcium phosphate on hydroxyapatite ceramic. Curr. Appl. Phys. 2005, 5:526-530.
8. Sogo Y., Ito A., Onoguchi M., et al. Formation of a FGF-2 and calcium phosphate composite layer on a hydroxyapatite ceramic for promoting bone formation. Biomed. Mater. 2007, 2:S175-180.
9. Tsurushima H., Marushima A., Suzuki K., et al. Enhanced bone formation using hydroxyapatite ceramic coated with fibroblast growth factor-2. Acta Biomater. 2010, 6:2751-2759.
10. Brint S., Jacewicz M., Kiessling M., et al. Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J. Cereb. Blood Flow Metab. 1988, 8:474-485.
11. Kawaguchi M., Drummond J.C., Cole D.J., et al. Effect of isoflurane on neuronal apoptosis in rats subjected to focal cerebral ischemia. Anesth. Analg. 2004, 98:798-805.
12. Tanaka R., Miyasaka Y., Yada K., et al. Basic fibroblast growth factor increases regional cerebral blood flow and reduces infarct size after experimental ischemia in a rat model. Stroke 1995, 26:2154-2158; discussion 2158-2159.
13. Krupinski J., Kaluza J., Kumar P., et al. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994, 25:1794-1798.
14. Font M.A., Arboix A., Krupinski J. Angiogenesis, neurogenesis and neuroplasticity in ischemic stroke. Curr. Cardiol. Rev. 2010, 6:238-244.
15. Liu Y., Lu J.B., Ye Z.R. Permeability of injured blood brain barrier for exogenous bFGF and protection mechanism of bFGF in rat brain ischemia. Neuropathology 2006, 26:257-266.
16. Seghezzi G., Patel S., Ren C.J., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 1998, 141:1659-1673.
17. Murakami M., Simons M. Fibroblast growth factor regulation of neovascularization. Curr. Opin. Hematol. 2008, 15:215-220.
18. Yuan A., Yu C.J., Shun C.T., et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int. J. Cancer 2005, 115:545-555.
19. Greitz D., Hannerz J. A proposed model of cerebrospinal fluid circulation: observations with radionuclide cisternography. AJNR. Am. J. Neuroradiol. 1996, 17:431-438.
20. Akimoto T., Hammeman M.R. Fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta. Am. J. Physiol. Cell. Physiol. 2003, 284:C371-C377.
21. Busch H.J., Buschmann I.R., Mies G., et al. Arteriogenesis in hypoperfused rat brain. J. Cereb. Blood Flow Metab. 2003, 23:621-628.
22. Masaki I., Yonemitsu Y., Yamashita A., et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ. Res. 2002, 90:966-973.
23. Cuevas P., Carceller F., Ortega S., et al. Hypotensive activity of fibroblast growth factor. Science 1991, 254:1208-1210.
24. Jiang N., Finklestein S.P., Do T., et al. Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat. J. Neurol. Sci. 1996, 139:173-179.
25. Yamamoto M., Sakakibara Y., Nishimura K., et al. Improved therapeutic efficacy in cardiomyocyte transplantation for myocardial infarction with release system of basic fibroblast growth factor. Artif. Organs 2003, 27:181-184.
26. Hong L., Tabata Y., Miyamoto S., et al. Bone regeneration at rabbit skull defects treated with transforming growth factor-beta1 incorporated into hydrogels with different levels of biodegradability. J. Neurosurg. 2000, 92:315-325.